Artiva Biotherapeutics Shuts Down Autoimmune Cell Therapy Trial and Cuts 94 Percent of Workforce

Artiva Biotherapeutics is halting all clinical development of its lead autoimmune cell therapy and laying off 94 percent of its workforce following two patient deaths. The San Diego-based biotechnology company announced the sweeping cuts on Tuesday, effectively shutting down its primary research operations.[1][2]

The company had been testing AlloNK, an off-the-shelf natural killer cell therapy, as a treatment for rheumatoid arthritis and other B-cell-driven autoimmune conditions. Artiva was preparing to launch a pivotal Phase 3 trial later this year before a risk-benefit review forced the sudden reversal.[1][4]

AlloNK was designed as a non-genetically modified, cryopreserved therapy that could be manufactured in bulk and stored for immediate use. Unlike autologous cell therapies, which require harvesting and engineering a patient's own cells, Artiva's approach aimed to bypass complex manufacturing delays and reduce treatment costs.[1][4]

The two fatalities occurred during a Phase 2a basket trial evaluating the therapy in combination with the monoclonal antibody rituximab. One participant suffered a fatal neurological event, known as leukoencephalopathy, which causes severe damage to the brain's white matter.[2][4]

Trial investigators and an independent safety review board linked the neurological death to fludarabine, a chemotherapy drug used in the trial's conditioning regimen. Patients must undergo this lymphodepletion process to clear out their existing white blood cells before receiving the experimental cell therapy.[1][2]

Fludarabine is a potent chemotherapy agent traditionally used to treat B-cell malignancies like chronic lymphocytic leukemia. In the Artiva trial, the affected patient developed progressive neurological symptoms approximately five weeks after receiving their first fludarabine dose, and died five weeks later.[2]

Following the first fatality, the US Food and Drug Administration instructed Artiva to pause all enrollment and dosing in the Phase 2a study. The company subsequently halted its plans to advance the therapy into late-stage clinical testing.[2][4]

Unexplained fatality and fading efficacy

The second trial participant died suddenly approximately two months after initiating the treatment regimen. The trial investigator determined that this fatality was unrelated to the AlloNK therapy or the chemotherapy conditioning, though the exact cause of death remains undetermined.[1][4]

Beyond the severe safety events, Artiva disclosed that the therapy was failing to maintain its therapeutic effects over time. While early data demonstrated deep B-cell depletion, longer-term follow-up revealed that the clinical responses lacked the durability required to support further development.[3][4]

As of an April 2026 data cutoff, Artiva reported that five out of seven patients with refractory rheumatoid arthritis had achieved a standard clinical response metric at six months. However, as those patients were tracked further into the year, the disease suppression failed to hold.[4]

The company had also tested the therapy in 11 patients with Sjögren's disease, reporting initial improvements on a standard disease activity index in early October 2026. Ultimately, the combination of fading efficacy across multiple indications and the Grade 5 safety events forced the board's hand.[4]

"After careful consideration, we have made the difficult decision to discontinue development of AlloNK and to pursue strategic alternatives," Artiva Chief Executive Officer Fred Aslan said in a statement. The company noted that patient safety remained its highest priority throughout the clinical program.[5]

The clinical failure triggers a near-total liquidation of the company's human capital. Artiva reported having 115 full-time employees as of June 30, 2026; the 94 percent workforce reduction will eliminate approximately 108 positions, leaving fewer than 10 staff members to manage the wind-down.[2][4]

The mass layoffs are expected to be completed by the first quarter of 2027. The remaining skeleton crew will work with the FDA, trial investigators, and institutional review boards to execute an orderly close-out of the clinical program.[4]

A broader crisis for autoimmune cell therapies

Artiva's collapse highlights a growing safety crisis at the intersection of cell therapy and autoimmune disease research. Dozens of biotechnology companies have recently pivoted their oncology cell therapies toward conditions like lupus and rheumatoid arthritis, hoping to reset malfunctioning immune systems.[2]

These treatments rely on harsh chemotherapy regimens to prepare the patient's body for the engineered cells. While oncologists routinely accept the severe toxicities of lymphodepletion when treating terminal blood cancers, deploying those same chemotherapy drugs for non-fatal autoimmune conditions fundamentally alters the risk-benefit calculation.[2]

Artiva is now the third major drugmaker to report fatal events in an autoimmune cell therapy trial in recent months. In August 2026, Novartis paused its CD19 program after three patients died from a severe immune reaction known as hemophagocytic syndrome.[1][2]

Bristol Myers Squibb also paused its autoimmune cell therapy efforts over the summer after observing transient inflammatory events. Just days before Artiva's announcement, Bristol Myers reported another patient death in a separate clinical trial evaluating a cell therapy for multiple sclerosis.[1][2]

Despite the mounting death toll across the sector, some industry leaders maintain that the underlying science remains valid. "There is an important segment with severe and refractory disease that are in need of therapies that actually work," Aslan told Endpoints News following the shutdown.[2]

Strategic alternatives and financial fallout

The clinical shutdown represents a massive financial reversal for a company that successfully raised $300 million in a May 2026 share offering. Just last month, Artiva had outlined ambitious plans to share updated efficacy data and expand its clinical footprint.[3][4]

The company now holds a substantial cash reserve, reporting $319.1 million in preliminary cash, cash equivalents, and investments as of September 30, 2026. Artiva's board of directors has engaged Leerink Partners as a financial advisor to help determine the company's next steps.[4]

The board is currently evaluating a range of strategic alternatives to maximize shareholder value. These options include a potential merger, a business combination, the sale or licensing of the company's remaining technological assets, or a complete dissolution and liquidation.[2][4]

Analysts suggest that while the cash pile might attract a buyer looking for a reverse merger, the clinical failure leaves little inherent value in the pipeline. The company stated it will not provide further updates on the strategic process until the board approves a specific course of action.[1][4]